STOCK TITAN

Spectral AI, Inc. - MDAI STOCK NEWS

Welcome to our dedicated page for Spectral AI news (Ticker: MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.

Spectral AI, Inc. (Nasdaq: MDAI) is an artificial intelligence company dedicated to advancing medical diagnostics, particularly in wound care. The company's flagship product, the DeepView™ System, is a cutting-edge multispectral imaging (MSI) device designed to assist physicians in making accurate and timely treatment decisions. This innovative technology leverages proprietary algorithms to differentiate between damaged and healthy tissue, producing critical Day One healing assessments within seconds.

Spectral AI's DeepView System has received FDA Breakthrough Device Designation due to its potential to significantly improve patient outcomes. The primary focus of the company lies in the research and development of this system. Notably, a substantial portion of its funding comes from the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.

In recent developments, Spectral AI was honored with the Commitment to Quality Achievement Award by the Texas Manufacturer Assistance Center (TMAC) for their attainment of the UKCA Mark. This accolade underscores the company’s dedication to maintaining the highest standards of quality while working towards the commercialization of DeepView technology.

The company frequently updates its stakeholders through conference calls and presentations, which can be accessed via the investor relations section of its website. This proactive communication strategy ensures transparency and keeps investors well-informed about the company's progress and financial health.

Investor Relations Contacts:

Devin Sullivan, Managing Director at The Equity Group, can be reached at dsullivan@equityny.com.

Conor Rodriguez, Analyst at The Equity Group, can be contacted at crodriguez@equityny.com.

Media Contacts:

David Schull of Russo Partners can be reached at david.schull@russopartnersllc.com or (858) 717-2310.

Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a Letter to Shareholders detailing the Company's progress towards commercializing its AI-driven DeepView System for wound assessment and treatment. The letter highlights a $149 million contract from BARDA, revenue generation expectations, FDA and UKCA marking for proprietary technology, promising interim results for DFU Clinical Study, and new management appointments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
AI
-
Rhea-AI Summary
Spectral MD, Inc. announces the submission of an application in the UK for its predictive software DeepView AI®-Burn to be registered as UK Conformity Assessed for burn wound use. This marks a significant step towards commercialization for the company's AI software in the medical diagnostics field, specifically for thermal burn wounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) announces the enrollment of the first patient in the pivotal study to validate DeepView AI® for burn size and healing assessment. The study is expected to be the final clinical trial before seeking FDA marketing authorization in 2025. The company continues to utilize $251 million of non-dilutive government funding since 2019 to validate DeepView for burn indication and other clinical indications like diabetic foot ulcers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) has announced the hiring of Peter M. Carlson as Chief Financial Officer. Carlson brings a strong track record in senior financial executive roles at public companies, including healthcare entities, and will play a crucial role in navigating the financial landscape and strategic opportunities for Spectral AI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.23%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) is an AI company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care. The company announced its participation in the Benchmark 12th Annual Discovery One-on-One Conference in New York City. Spectral AI's DeepView® System has received a significant contract from the U.S. Government and has been validated through multiple clinical studies for assessing burn wounds and diabetic foot ulcers. The company expects to submit applications for FDA, UKCA, and CE mark approval for its DeepView® System in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.96%
Tags
conferences AI
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) appoints Erich Spangenberg as Chairman of the Executive Committee and Nominating and Corporate Governance Committee. Erich, the Company's largest shareholder, brings 40 years of experience in IP-related financings and is recognized as a top 50 IP strategist. Spectral AI received $251 million in non-dilutive funding from the US Government, and Erich aims to maximize shareholder value and reflect the intrinsic value of MDAI stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced Q3 2023 financial results, affirming full-year revenue guidance for 2023 and 2024. The company highlighted progress in developing and commercializing its AI-Driven DeepView® System wound healing assessment technology. The system provides immediate wound healing potential assessment, with high accuracy for burn and diabetic foot ulcers. The company is preparing for the commercial launch of the DeepView® System as early as 2024, following regulatory approvals. Q3 2023 financial results overview showed a decline in R&D revenue, gross margin, and an increase in general & administrative expenses. The net loss was $(10.6) million, and cash and cash equivalents totaled $7.3 million as of September 30, 2023. The company reaffirmed its revenue guidance for full year 2023 and 2024, expecting 2024 revenue growth of approximately 60% from anticipated 2023 levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. will report financial results for Q3 2023 on November 13, 2023. A conference call to discuss the results will be held on November 14, 2023. Investors can access the webcast of the call on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.2%
Tags
-
Rhea-AI Summary
Spectral AI appoints Prof. Paul Chadwick as Executive VP of its UK subsidiary to expand the international market for its DeepView® wound imaging technology. Prof. Chadwick brings extensive experience in the medical devices and technology sectors, particularly in diabetic wound management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
AI
Rhea-AI Summary
Spectral AI provides annual revenue guidance for 2023 and 2024 and highlights opportunities with its AI-Driven DeepView® Wound Imaging Technology. The company recently secured a contract valued at over $149.0 million from the U.S. Government.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
AI

FAQ

What is the current stock price of Spectral AI (MDAI)?

The current stock price of Spectral AI (MDAI) is $1.29 as of September 13, 2024.

What is the market cap of Spectral AI (MDAI)?

The market cap of Spectral AI (MDAI) is approximately 22.1M.

What does Spectral AI, Inc. specialize in?

Spectral AI specializes in AI-based medical diagnostics, particularly focusing on wound care through their DeepView System.

What is the DeepView System?

The DeepView System is a multispectral imaging device that uses AI algorithms to distinguish between damaged and healthy tissue, aiding in quicker and more accurate treatment decisions.

Has the DeepView System received any regulatory recognition?

Yes, the DeepView System has received FDA Breakthrough Device Designation.

Where does Spectral AI get its research funding?

A substantial portion of Spectral AI's funding comes from the Biomedical Advanced Research and Development Authority (BARDA).

What recent award has Spectral AI received?

Spectral AI recently received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center.

How can investors stay updated on Spectral AI's progress?

Investors can stay updated through conference calls and presentations available on the investor relations section of the company's website.

Who are the media contacts for Spectral AI?

David Schull of Russo Partners, reachable at david.schull@russopartnersllc.com or (858) 717-2310, is the media contact.

What is the role of BARDA in Spectral AI's operations?

BARDA provides essential research and development funding for Spectral AI's projects.

What kind of assessments does the DeepView System provide?

The DeepView System provides Day One healing assessments, allowing for accurate and timely treatment decisions.

Who are the investor relations contacts at Spectral AI?

Devin Sullivan, Managing Director, and Conor Rodriguez, Analyst, both at The Equity Group, are the investor relations contacts.

Spectral AI, Inc.

Nasdaq:MDAI

MDAI Rankings

MDAI Stock Data

22.10M
17.61M
46.74%
21.01%
3.38%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
DALLAS